FLYNN MCCULLOUGH: Open Payments
NPI 1023542271 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,572 in 90 payments from 14 companies in 2025. Trend: 2023 $1,966 · 2024 $1,607 · 2025 $1,572
Food & beverage: $1,572
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $255 |
| Vanda Pharmaceuticals Inc. | 16 | $233 |
| Lundbeck LLC | 11 | $193 |
| Corium, LLC | 11 | $193 |
| Teva Pharmaceuticals USA, Inc. | 7 | $153 |
| Neurocrine BioSciences, Inc. | 6 | $111 |
| E.R. Squibb & Sons, L.L.C. | 5 | $101 |
| ABBVIE INC. | 4 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $67 |
| Alkermes, Inc. | 3 | $57 |
Products named: REXULTI, Azstarys, HETLIOZ, AUSTEDO XR, INGREZZA, FANAPT, COBENFY, VRAYLAR.
Industry payments across IA — which companies pay providers there.
